Nchi: Afrika Kusini
Lugha: Kiingereza
Chanzo: South African Health Products Regulatory Authority (SAHPRA)
Schering
ANDROCUR DEPOT SCHEDULING STATUS: S4 PROPRIETARY NAME (and dosage form): ANDROCUR DEPOT Antiandrogen injection COMPOSITION One 3 mL ampoule Androcur Depot contains cyproterone acetate (6-chloro-17-hydroxy-1alpha,2alpha-methylene- pregna-4,6-diene-3,20-dione-acetate) 300 mg in oily solution. PHARMACOLOGICAL CLASSIFICATION A. 21.12 Hormone inhibitors. PHARMACOLOGICAL ACTION Androcur is an antiandrogenic hormone preparation. The active substance, cyproterone acetate, has three partial effects: an antiandrogenic effect, a progestational effect and an antigonadotropic effect. Cyproterone acetate blocks the effect of endogenously produced and exogenously administered androgens at the target organs by means of competitive inhibition. The stimulating effect of male sex hormones on androgen dependent structures and functions is weakened or abolished by cyproterone acetate. The inherent progestational activity exerts a negative feedback on the hypothalamic receptors so leading to a reduction in gonadotropin release, and hence to diminished production of androgens. INDICATIONS Reduction of drive in sexual deviations in the male; inoperable prostatic carcinoma. CONTRA-INDICATIONS Androcur Depot is contra-indicated in patients with liver diseases; Dubin-Johnson syndrome; Rotor syndrome; previous or existing liver tumours (in carcinoma of the prostate only if these are not due to metastases); wasting diseases (with the exception of prostatic carcinoma); depression; previous or existing thromboembolic processes; diabetes with vascular changes; sickle-cell anaemia. As regards patients with prostatic carcinoma who have a history of thromboembolic processes and/or an existing sickle- cell anaemia, or diabetes with vascular changes, the risk:benefit ratio must be considered carefully in each individual case before the use of And Soma hati kamili